Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...

The US regulator has approved the first-line use of Vanflyta (quizartinib) in combination with standard cytarabine/anthracycline induction therapy and cytarabine consolidation therapy for these ...